相关实验视频

Updated: Jul 7, 2025

An Oncogenic Hepatocyte-Induced Orthotopic Mouse Model of Hepatocellular Cancer Arising in the Setting of Hepatic Inflammation and Fibrosis

An Oncogenic Hepatocyte-Induced Orthotopic Mouse Model of Hepatocellular Cancer Arising in the Setting of Hepatic Inflammation and Fibrosis

Published on: September 12, 2019

托法西替尼在治疗耐火性免疫检查点抑制剂肝炎方面有效

Mike Wang¹, Kerry L Reynolds¹, Kamaneh Montazeri¹

¹Mass General Cancer Center, Massachusetts General Hospital, Boston, Massachusetts; Harvard Medical School, Boston, Massachusetts.

Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association

|December 24, 2023

概括

当标准疗法失败时,托法西提尼布为免疫检查点抑制剂肝炎提供了潜在的新疗法. 这种Janus激酶 (JAK) 抑制剂在三个耐火病例中显示出有前途,扩大了管理这种严重免疫疗法副作用的选择.

科学领域:

在瘤学瘤学.
免疫学免疫学免疫学
肝病学肝病学是一种肝病学.

背景情况:

免疫检查点抑制剂 (ICI) 增强癌症治疗,但可能导致严重的免疫相关不良事件,如肝炎.
对ICI肝炎的标准治疗方法,包括葡萄糖皮质类药物和抗代谢剂,并不总是有效的.
对于耐火性ICI肝炎患者,治疗选择有限.

研究的目的:

报告三名患有抗葡萄糖皮质醇耐药免疫检查点抑制剂肝炎的患者的结果,这些患者接受了托法西提尼布治疗.
评估托法西提尼布作为重症ICI肝炎的救援疗法的安全性和有效性.

主要方法:

三名连续患者的回顾性病例系列.
患者接受托法西提尼布用于免疫检查点抑制剂 - - 耐标准系统性葡萄糖皮质体和抗代谢物治疗的肝炎.
数据收集自马萨诸塞州总医院严重免疫疗法并发症服务.

主要成果:

这三个患有耐火性ICI肝炎的患者都接受了托法西提尼布治疗.
托法西提尼布用于未能成功接受标准组合治疗的患者.
这些代表了在研究期间使用托法西提尼布治疗的唯一病例.

结论:

托法西替尼可能是严重免疫检查点抑制剂肝炎患者的可行的治疗选择,这些患者对已建立的疗法具有耐药性.
需要进一步的研究来证实JAK抑制剂在治疗ICI诱导的肝炎方面的疗效和安全性.

更多相关视频

Quantification of the Immunosuppressant Tacrolimus on Dried Blood Spots Using LC-MS/MS

Quantification of the Immunosuppressant Tacrolimus on Dried Blood Spots Using LC-MS/MS

Published on: November 8, 2015

Scaled-Up Preparation of an Intermediate of Upatinib, ACT051-3

Scaled-Up Preparation of an Intermediate of Upatinib, ACT051-3

Published on: April 7, 2023

相关概念视频

Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF

Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF

Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...

Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents

Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents

Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...

Tumor Immunotherapy

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.